Target concentration intervention in oncology: Where are we at?

Therapeutic Drug Monitoring

Volumn 34, Issue 3, 2012, Pages 257-265

  Saleem, Mohamed ^a,b   Dimeski, Goce ^b,c   Kirkpatrick, Carl M ^a,d   Taylor, Paul J ^a,c   Martin, Jennifer H ^a,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b IMVS/SA Pathology ^*  (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

Chemotherapy; Oncology; Pharmacokinetics; Target concentration intervention; Therapeutic drug monitoring

Indexed keywords

BUSULFAN; CARBOPLATIN; FLUOROURACIL; IMATINIB; METHOTREXATE;

ACUTE LYMPHOCYTIC LEUKEMIA; AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CLINICAL PRACTICE; DIARRHEA; DRUG BLOOD LEVEL; DRUG MONITORING; EVIDENCE BASED PRACTICE; HAND FOOT SYNDROME; HUMAN; INTERSTITIAL PNEUMONIA; LIVER VEIN OBSTRUCTION; OBESITY; ONCOLOGY; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; TARGET CONCENTRATION INTERVENTION; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY SURFACE AREA; DRUG DELIVERY SYSTEMS; DRUG MONITORING; HUMANS; NEOPLASMS; TREATMENT OUTCOME;

EID: 84861226483     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182557342     Document Type: Review

References (96)

1. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295: 1549-1555.
2. Australian Bureau of Statistics. Australian Social Trends 2004. Available at: http://www.abs.gov.au. Accessed September 2011.
3. Ratain MJ, Schilsky RL, Conley BA, et al. Pharmacodynamics in cancer therapy. J Clin Oncol. 1990;8:1739-1753. (Pubitemid 20334330)
4. Gibaldi M. Revisiting some factors contributing to variability. Ann Pharmacother. 1992;26:1002-1007.
5. Field KM, Kosmider S, Jefford M, et al. Chemotherapy dosing strategies in the obese, elderly, and thin patients: results of a nationwide survey. J Oncol Pract. 2008;4:111-116.
6. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low doseintensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21:4524-4531. (Pubitemid 46594022)
7. Shayne M, Culakova E, Poniewierski MS, et al. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer. 2007;110:1611-1620. (Pubitemid 47463077)
8. Madarnas Y, Sawka C, Franssen E, et al. Are medical oncologists biased in their treatment of the large woman with breast cancer? Breast Cancer Res Treat. 2001;66:123-133. (Pubitemid 32521418)
9. Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med. 2005;165: 1267-1273. (Pubitemid 40989591)
10. Shayne M, Crawford J, Dale DC, et al. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat. 2006;100:255-262. (Pubitemid 44707919)
11. Colleoni M, Li S, Gelber RD, et al. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet. 2005;368:1108-1110. (Pubitemid 41338765)
12. Holford NGH. Target concentration intervention: beyond Y2K. Br J Clin Pharm. 1999;48:9-13.
13. Begg EJ, Barclay ML, Kirkpatrick CM. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol. 2001;52(suppl 1): 35S-43S. (Pubitemid 32823030)
14. Johnston A, Holt DW. Immunosuppressant drugs-the role of therapeutic drug monitoring. Br J Clin Pharmacol. 2001;52(suppl 1): 61S-73S. (Pubitemid 32823033)
15. Crom WR, Evans WE. Methotrexate. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. 3rd ed. Vancouver, WA: Applied Therapeutics Inc. 1992:29.1-29.42.
16. Moore MJ, Erlichman C. Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy. Clin Pharmacokinet. 1987;13:205-227. (Pubitemid 17165719)
17. Evans WE, Relling MV. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet. 1989;16:327-336. (Pubitemid 19167714)
18. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol. 2005;20:1149-1157. (Pubitemid 41602556)
19. Touw DJ, Neef C, Thomson AH, et al. Cost-effectiveness of therapeutic drug monitoring: a systematic review. Committee of the International Association for Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit. 2005;27:10-17.
20. DeVita VT. Principles of cancer management: chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer. Principles and Practice of Oncology. 5th ed. Philadelphia, PA: Lippincott; 1997:333-347.
21. Adaway JE, Keevil BG. Therapeutic drug monitoring and LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;883-884:33-49.
22. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatory Information/EnforcementActivitiesbyFDA/WarningLettersandNoticeof ViolationLetterstoPharmaceuticalCompanies/ucm259229.htm. Accessed February 2012.
23. Norris RL, Martin JH, Thompson E, et al. Current status of therapeutic drug monitoring in Australia and New Zealand: a need for improved assay evaluation, best practice guidelines, and professional development. Ther Drug Monit. 2010;32:615-623.
24. Gamelin E, Boisdron-Celle M. Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer-status of the art. Crit Rev Oncol Hematol. 1999;30:71-79. (Pubitemid 29294713)
25. Porta-Oltra B, Perez-Ruixo JJ, Climente-Martin, et al. Population pharmacokinetics of 5-fluorouracil in colorectal cancer patients. J Oncol Pharm Prac. 2004;10:155-167. (Pubitemid 39406667)
26. McCune JS, Salinger DH, Vicini P, et al. Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the children's oncology group. J Clin Pharmacol. 2009;49: 88-102.
27. Ralph LD, Thomson AH, Dobbs NA, et al. A population model of epirubicin pharmacokinetics and application to dosage guidelines. Cancer Chemother Pharmacol. 2003;52:34-40. (Pubitemid 36920626)
28. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet. 1999;36:99-114. (Pubitemid 29121684)
29. Joerger M, Huitema AD, Richel DJ, et al. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. Clin Pharmacokinet. 2007;46:1051-1068. (Pubitemid 350136911)
30. Slaviero KA, Clarke SJ, McLachlan AJ, et al. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br J Clin Pharmacol. 2004;57:44-53. (Pubitemid 38067949)
31. Hunz M, Jetter A, Warm M, et al. Plasma and tissue pharmacokinetics of epirubicin and paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer. Clin Pharmacol Ther. 2007; 81:659-668. (Pubitemid 46625101)
32. Joerger M, Huitema AD, Richel DJ, et al. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group. Clin Cancer Res. 2007;13:6410-6418. (Pubitemid 350075031)
33. Sandström M, Lindman H, Nygren P, et al. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin- cyclophosphamide regimen in breast cancer patients. Cancer Chemother Pharmacol. 2006;58:143-156.
34. Evans WE, Crom WR, Stewart CF, et al. Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukemia. Lancet. 1984;18:359-362. (Pubitemid 14183279)
35. Evans WE, Crom WR, Abromowitch M, et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. N Engl J Med. 1986;314:471-477.
36. Borsi JD, Moe PJ. Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children. Cancer. 1987;60:3020-3024. (Pubitemid 18005878)
37. Evans WE, Relling MV, Rodman JH, et al. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med. 1998;338:499-505. (Pubitemid 28103133)
38. Saeter G, Alvegard TA, et al. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol. 1991;9:1766-1775.
39. Jodrell DI, Egorun MJ, Cannetta RM, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol. 1992;10:520-528.
40. Horwich A, Dearnaley DP, Nicholls J, et al. Effectiveness of carboplatin, etoposide and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors. J Clin Oncol. 1991;9:62-67.
41. Milano G, Etienne MC, Renee N, et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol. 1994;12:1291-1295. (Pubitemid 24173946)
42. Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, et al. Relationship between 5-fluorouracil (FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing FU. Cancer. 1996;77:441-451. (Pubitemid 26047564)
43. Gamelin E, Delva R, Jacob J, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:2009-2105.
44. Di Paolo A, Lencioni M, Amatori F, et al. 5-Fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. Clin Cancer Res. 2008;14: 2749-2755.
45. Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 1989;25:55-61. (Pubitemid 20000799)
46. Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics [published erratum appears in Bone Marrow Transplant 1996; 18:829]. Bone Marrow Transplant. 1995;16:31-42.
47. Dix SP, Wingard JR, Mullins RE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant. 1996;17:225-230. (Pubitemid 26057312)
48. Hassan M, Oberg G, Ljungman P, et al.Correlation between hepatic veno-occlusive disease (VOD) and busulphan levels using limited sampling model for dose estimation. 39th Annual Meeting of the American Society of Hematology; 1997 December 5-7; San Diego, CA. Blood. 1997;90(suppl):1106A.
49. Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111:4022-4028.
50. Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard dose imatinib in chronic myeloid leukemia. Blood. 2007;109:3496-3499. (Pubitemid 46572540)
51. Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol. 2009;27:3141-3147.
52. Martin JH, Saleem M, Looke D. Therapeutic drug monitoring to adjust dosing in morbid obesity-a new use for an old methodology. Br J Clin Pharmacol. 2012; 73: 685-690.
53. Camitta B, Leventhal B, Lauer S, et al. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood; a Pediatric Oncology Group study. J Clin Oncol. 1989;7:1539-1544. (Pubitemid 19245127)
54. Evans WE, Rodman J, Relling MV, et al. Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia. Semin Hematol. 1991;28(suppl 4):15-21.
55. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360: 2730-2741.
56. Graf N, Winkler K, Betlemovic N, et al. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol. 1994;12:1443-1451. (Pubitemid 24206244)
57. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7:1748-1756. (Pubitemid 19272848)
58. Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst. 1995;87:573-580.
59. Sørensen BT, Strömgren A, Jakobsen P, et al. Alimited sampling method for estimation of the carboplatin area under the curve. Cancer Chemother Pharmacol. 1993;31:324-327. (Pubitemid 23029159)
60. Ghazal-Aswad S, Calvert AH, Newell DR. A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve. Cancer Chemother Pharmacol. 1996;37:429-434. (Pubitemid 26054551)
61. Asai G, Ando Y, Saka H, et al. Estimation of the area under the concentration-versus-time curve of carboplatin following irinotecan using a limited sampling model. Eur J Clin Pharmacol. 1998;54:725-727. (Pubitemid 29024205)
62. Nannan Panday VR, van Warmerdam LJC, Huizing MT, et al. A limited sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel. J Cancer Res Clin Oncol. 1999;125:615-620. (Pubitemid 29502342)
63. Egorin MJ, Van Echo DA, Tipping SJ, et al. Pharmacokinetics and dosage reductions of cisdiammine(1,1 cyclobutanedicarboxylato) platinum in patients with impaired renal function. Cancer Res. 1984;44: 5432-5438. (Pubitemid 15204524)
64. Egorun MJ, Van Echo DA, Olman EA, et al. Prospective validation of a pharmacologically based dosing scheme for cisdianimunedichloroplatinum( Il) analogue of diamminecyclobutane dicarboxylatoplatinum. Cancer Res. 1985;45:6502-6506. (Pubitemid 16224834)
65. Guillet P, Monjanel S, Nicoara A, et al. A Bayesian dosing method for carboplatin given by continuous infusion for 120 h. Cancer Chemother Pharmacol. 1997;40:143-149. (Pubitemid 27214593)
66. Johansen MJ, Madden T, Mehra RC, et al. Phase I pharmaco kinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer. J Clin Oncol. 1997;15: 1481-1491. (Pubitemid 27167384)
67. Veal GJ, Foot A, McDowell H, et al. Optimization of high dose carboplatin treatment in children with stage IV soft tissue sarcoma (SIOP/UKCCSG MMT 98 study) by real-time pharchemotherapy. macokinetic monitoring [abstract]. Proc Am Assoc Cancer Res. 2002;43:275.
68. Rubie H, Doz G, Vassal G, et al. Individual dosing of carboplatin based on drug monitoring in children receiving high-dose chemotherapy. Eur J Cancer. 2003;39:1433-1438. (Pubitemid 36773787)
69. Veal GJ, Errington E, Tilby MJ, et al. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours. Br J Cancer. 2007;96:725-731. (Pubitemid 46376616)
70. Allen S, Wilson MW, Watkins A, et al. Comparison of two methods for carboplatin dosing in children with retinoblastoma. Pediatr Blood Cancer. 2010;55:47-54.
71. Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer. 2002; 38:1677-1684.
72. Gamelin E, Boisdron-Celle M, Delva R, et al. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol. 1998;16:1470-1478. (Pubitemid 28175768)
73. Trump DL, Egorin MJ, Forrest A, et al. Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. J Clin Oncol. 1991;9:2027-2035.
74. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors (RECIST Guidelines). J Natl Cancer Inst. 2000;92:205-216. (Pubitemid 30099779)
75. van Kuilenburg AB, Häusler P, Schalhorn A, et al. Fluorouracil pharmacokinetics in cancer patients with a c.1905+1G.a mutation in DPYD by means of a Bayesian limited sampling strategy. Clin Pharmacokinet. 2012;51:163-174.
76. Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol. 1993;20: 18-25. (Pubitemid 23239401)
77. Kashyap A, Synold T, Parker P, et al. First dose area under the curve (AUC) of oral busulfan predicts risk of developing veno-occlusive diseases (VOD) in adult allogeneic bone marrow transplant (BMT) patients [abstract]. Proc Am Soc Clin Oncol. 1997;16:215a.
78. Ljungman P, Hassan M, Bekassy AN, et al. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant. 1997;20:909-913. (Pubitemid 27510952)
79. Vassal G, Deroussent A, Challine D, et al. A. Is 600 mg/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood. 1992;79:2475-2479.
80. Pawlowska AB, Blazar BR, Angelucci E, et al. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassaemia. Bone Marrow Transplant. 1997;20:915-920. (Pubitemid 27510953)
81. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997;89:3055-3060. (Pubitemid 27172594)
82. Baker KS, Bostrom B, DeFor T, et al. Busulfan pharmacokinetics do not predict relapse in acute myelogenous leukemia [abstract]. Blood. 1999; 94:144a.
83. Bolinger AM, Zangwill AB, Slattery JT, et al. Target dose adjustment of busulfan using pharmacokinetic parameters in pediatric patients undergoing bone marrow transplantation for malignancy or genetic disease [abstract]. Blood. 1999;94:145a.
84. Dennison D, Chandy M, Poonkuzhali B, et al. Plasma busulfan levels influence rejection in bone marrow transplantation for homozygous beta thalassaemia [abstract]. Blood. 1998;91:127a.
85. Nath CE, Earl JW, Pati N, et al. Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients. Br J Clin Pharmacol. 2008;66:50-59. (Pubitemid 351822161)
86. Bartelink IH, Bredius RG, Ververs TT, et al. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008;14:88-98. (Pubitemid 350286741)
87. Bartelink IH, Bredius RG, Belitser SV, et al. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15: 231-241.
88. Malar R, Sjoo F, Rentsch K, et al. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients. Pediatr Transplant. 2011;15:580-588.
89. Gibbs JP, Gooley T, Corneau B, et al. The impact of obesity and disease on busulfan oral clearance in adults. Blood. 1999;12:4436-4440. (Pubitemid 29279287)
90. Johnson-Davis KL, McMillin GA, Juenke JM, et al. Which dose of busulfan is best? Clin Chem. 2010;56:1061-1064.
91. Peng BM, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol. 2004;22:935-942. (Pubitemid 41103606)
92. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;444:879-894. (Pubitemid 41252840)
93. Mahon F, Bouchet S, Etienne G, et al. Management of chronic myelogenous leukemia using therapeutic drug monitoring of imatinib: the French experience of a centralized laboratory (abstract). J Clin Oncol. 2008;26:7087.
94. Takahashi N, Wakita H, Miura M, et al. Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronicphase chronic myeloid leukemia. Clin Pharmacol Ther. 2010;88: 809-813.
95. Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381-2388.
96. Gotta V, Widmer N, Montemurro M, et al. Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels. Clin Pharmacokinet. 2012;51:187-201.